



Rectosigmoid ischemia and cerebral coma following gadolinium-induced anaphylaxis: A new manifestation of Kounis syndrome presented as devastating complication

Gadolinium-based contrast mediums are the most commonly used agents in magnetic resonance imaging for both angiography, and brain tumor enhancement due to their association with the degradation of the blood-brain barrier. When oxidation is removed from gadolinium medium and gadolinium salts, a silvery-white metal anions remain that are able to induce allergic reactions and anaphylaxis. Whereas such reactions are not common, other reactions including nephrogenic systemic fibrosis and acute kidney injury due to primary excretion of gadolinium from the kidneys and various cardiac arrhythmias including QTc electrocardiographic prolongation are occasionally encountered^{1,2}. Despite that gadolinium-based contrast mediums are characterized as benign agents, in some occasions they can lead to life threatening conditions and Kounis syndrome²⁻⁵. The concurrence of acute coronary syndromes such as coronary spasm, acute myocardial infarction, and stent thrombosis, with conditions associated with mast-cell and platelet activation involving other interrelated and interacting inflammatory cells, such as macrophages and T-lymphocytes in the setting of allergic or hypersensitivity and anaphylactic or anaphylactoid insults constitute the Kounis syndrome⁶. This syndrome is caused by inflammatory mediators such as histamine, neutral proteases, arachidonic acid products, platelet-activating factor, and a variety of cytokines and chemokines released during the degranulation process of these inflammatory cells. Platelets bearing specific fragment crystallizable region receptors are also involved in the activation cascade⁷. All these inflammatory cells participate in an inflammatory cycle and activate each other via multidirectional signals.

The coronary arteries, the heart and the entire arterial system seem to be vulnerable to allergic, hypersensitivity, anaphylactic, and/or anaphylactoid events and physicians should be alert for their consequences. The incidence of Kounis syndrome⁸ ranges from 1.1% to 3.4%. Kounis syndrome was initially thought to be a rare condition but seems rather to be an under diagnosed disease. Three variants of this syndrome have been described

so far. They include the type I variant in patients with coronary artery spasm but with normal or nearly normal coronary arteries and no predisposing factors for coronary artery disease, the type II variant in patients with quiescent preexisting atheromatous disease who present with acute myocardial infarction and the type III variant in patients with coronary stent implantation who develop stent thrombosis (subtype a) or stent restenosis (subtype b) due to allergic inflammation⁹.

Recent research has shown that Kounis like syndromes can affect not only the coronary arteries but also the cerebral arteries^{10,11} and the mesenteric arteries¹².

In the very important report by Juliani et al in *Annali Italiani di Chirurgia*¹³, a 72-year-old woman suffering from anal squamous cell carcinoma and receiving mitomycin and fluorouracil chemotherapy and then radiotherapy, developed anaphylactic reaction to Gadolinium during regular magnetic resonance imaging, with shock and cardiac arrest, that lasted about half an hour before she was successfully resuscitated. Following this event the patient developed massive digestive bleeding that was successfully treated with Hemospray and passage of stool from the vagina due to the presence of a recto-vaginal fistula. The patient became comatose for about 30 days, during which she was uncontactable. Colonoscopy revealed rectosigmoid ischemia with total necrosis of the posterior rectal wall with exposition of presacral fascia. This report raises important issues concerning anaphylactic shock and cardiovascular collapse, and also anaphylactic shock and coma.

The sigmoid colon derives its name from a Greek letter sigma and constitutes a hindgut structure that receives its blood from the sigmoidal branches of the inferior mesenteric artery and collateral blood supply from the left colic artery and inferiorly from the superior rectal arteries. Both these branches also originate from the inferior mesenteric artery. The rectosigmoid junction is a major watershed zone known as Sudeck's point, which is prone to ischemia in states of decreased perfusion. Therefore, the question which arises in the case described by Juliani et al¹³, is whether systemic vasodilation or mesenteric vasoconstriction was the cause of a such devastating result during gadolinium-induced anaphylaxis. Indeed, systemic vasodilation can induce plasma leakage, volume loss due to increased vascular permeability, and reduced venous return resulting in mesenteric hypoperfusion. On the other hand, the mediators release during

anaphylaxis (histamine, chymase, tryptase, cathepsin D, leukotrienes, thromboxane, platelet activating factor) can cause rectosigmoid ischemia with total necrosis of the posterior rectal wall with exposition of presacral fascia.

In particular, the above mediators released during anaphylactic shock apply the following actions¹⁴: Histamine can induce coronary vasoconstriction via the H1 receptors, chymase and cathepsin-D convert angiotensin I to angiotensin II which are major vasoconstrictive substances, tryptase activates the zymogen forms of metalloproteinases such as interstitial collagenase, gelatinase, and stromelysin that can promote plaque disruption and induce pericellular matrix degradation (basophils have about 500-fold lower levels of tryptase than mast cells). Indeed, leukotrienes acting as powerful vasoconstrictors, thromboxane promoting platelet aggregation and vasoconstriction and platelet activating factor can further induce vasoconstriction.

As far as the coronary arterial tree there are experiments and clinical events that have shown the followings during anaphylaxis: In ovalbumin sensitized guinea pigs within 3 min post ovalbumin administration it was observed that¹⁵: Cardiac output decreased by 90%, left end ventricular diastolic pressure increased significantly by 35%, indicating pump failure, arterial blood pressure increased significantly by 35% and started declining steadily after 4 min and the electrocardiogram revealed signs of acute myocardial ischemia. The conclusion was that “the idea that the registered anaphylactic damage might be due to peripheral vasodilatation can be definitely excluded”. In addition, the rapid left end ventricular diastolic pressure increase suggests that decreased venous return and volume loss due to vascular permeability increase are unlikely to be the primary causes of the documented cardiac output and blood pressure depression.

Moreover, in the clinical setting there are studies demonstrating that, in anaphylaxis, cardiac biomarkers denoting myocardial injury are raised¹⁶. Additionally, there are also clinical reports of patients with anaphylactic cardiac collapse and Kounis syndrome with increased serum troponin, who did not respond to intravenous fluid administration and inotropic support and required coronary syndrome treatment protocol¹⁷.

In the described case¹³, the gadolinium induced anaphylactic shock, that was associated with cardiac arrest and coma, could had been the result of both mesenteric vasoconstriction causing ischemia and systemic vasodilatation inducing mesenteric hypovolemia.

In a recent study¹⁸, it was found that anaphylactic shock decreases cerebral blood flow more than what would be expected from severe arterial hypotension. The authors of this paper concluded that, in anaphylactic shock, severe impairment of the cerebral blood flow takes place, which could not be explained by the level of arterial hypotension.

Indeed, cerebral coma from irreversible diffuse hypoxic-ischemic encephalopathy has been described in a female patient following bee-sting induced Kounis syndrome as she is still in a vegetable state mechanically ventilated in the intensive care unit after 6 months⁸. In another patient, with Kounis syndrome, from Spain, anaphylactic reaction to amoxicillin-clavulanic acid under general anesthesia induced severe, irreversible and subsequently fatal encephalopathy of ischemic origin as a result of low blood pressure affecting the cerebral arterial system¹⁹.

Furthermore, transient cerebral ischemic attacks were developed in 2 patients with mast cell-related disorders while they had previous history of chest pain and Kounis-like syndrome²⁰. The first patient developed transient hemiparesis with decreased sensation and muscular weakness of the face and the second developed episodes of sudden transient paresis and numbness of his right arm following strenuous work that was re-developed during hospitalization.

All of the above show that the mesenteric and cerebral and arteries can be affected via the same mechanism as the coronary arteries through the action of anaphylactic mediators that can induce vasoconstriction, hypo-perfusion and thrombosis. Therefore, mesenteric and cerebral ischemia following anaphylactic shock could be due to direct action of anaphylactic mediators on the cerebral arterial system and not solely due to hypovolemic hypotension. Surgeons and physicians should be aware of the various manifestations of Kounis syndrome in order to apply prompt and appropriate therapeutic measures

References

1. Kirchin MA, Pirovano G, Venetianer C, Spinazzi A: *Safety assessment of gadobenate dimeglumine (MultiHance): Extended clinical experience from phase I studies to post-marketing surveillance*. J Magn Reson Imaging, 2001; 14:281-94.
2. Abusnina W, Shehata M, Abouzid M, et al.: *Kounis syndrome secondary to gadolinium contrast agent*. Proc (Bayl Univ Med Cent), 2019; 32: 253-55.
3. Tanaka H, Urushima M, Hirano S, Takenaga M: *An acute adverse reaction with st elevation induced by magnetic resonance contrast media: kounis syndrome*. Intern Med, 2019; 58:243-45.
4. Demoulin R, Poyet R, Capilla E, et al.: *Infarctus du myocarde inférieur compliqué de bloc auriculo-ventriculaire complet et d'arrêt cardiocirculatoire dans les suites d'une injection de gadolinium: à propos d'une observation de syndrome de Kounis [Inferior myocardial infarction complicated by complete heart block and cardiac arrest following a gadolinium injection: A case of Kounis syndrome]*. Ann Cardiol Angeiol (Paris), 2017; 66:319-22.
5. Memon S, Chhabra L, Masrur S, Parker MW: *Allergic acute coronary syndrome (Kounis syndrome)*. Proc (Bayl Univ Med Cent), 2015; 28:358-62.
6. Kounis NG, Koniari I, Velissaris D, et al.: *Kounis Syndrome*.

Not a Single-organ Arterial Disorder but a Multisystem and Multidisciplinary Disease. Balkan Med J, 2019; 36: 212-21.

7. Hasegawa S, Tashiro N, Matsubara T, et al.: *A comparison of FcεpsilonRI-mediated RANTES release from human platelets between allergic patients and healthy individuals.* Int Arch Allergy Immunol, 2001; 125(Suppl 1):42-47.

8. Kounis NG, Koniari I, Velissaris D, et al.: *Kounis Syndrome-not a single-organ arterial disorder but a multisystem and multidisciplinary disease.* Balkan Med J, 2019; 36: 212-21.

9. Kounis NG, Koniari I, Tsigkas G, Davlouros P: *Humanized monoclonal antibodies against ige antibodies as therapy for ige-mediated coronary syndromes: Are we there yet?* Can J Cardiol, 2020; 36: 816-19.

10. Anastogiannis H, Litsardopoulos P, Anastopoulou GG, et al.: *Irreversible diffuse hypoxic-ischemic encephalopathy, secondary to type I Kounis syndrome.* Int J Neurosci, 2020; 130: 746-48.

11. Peláez-Pérez JM, Sánchez Casado M, Álvarez-Twose I, Kounis NG. *Amoxicillin-clavulanic acid-induced type II Kounis syndrome during general anaesthesia complicated with hypoxic-ischaemic encephalopathy* [published online ahead of print, 2019 Aug 7]. Rev Esp Anesthesiol Reanim, 2019; S0034-9356(19)30123-9.

12. Goto M, Matsuzaki M, Fuchinoue A, et al.: *Chronic atherosclerotic mesenteric ischemia that started to develop symptoms just after anaphylaxis.* Case Rep Gastroenterol, 2012; 6:300-30.

13. Giuliani A, Romanzi F, Di Sibio A, et al.: *Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.* Ann Ital Chir, 2019; 8: S2239253X1903082

14. Kounis NG, Cervellin G, Koniari I, et al.: *Anaphylactic cardiovascular collapse and Kounis syndrome: Systemic vasodilation or coronary vasoconstriction?* Ann Transl Med, 2018; 6: 332.

15. Felix SB, Baumann G, Berdel WE: *Systemic anaphylaxis Separation of cardiac reactions from respiratory and peripheral vascular events.* Res Exp Med (Berl), 1990; 190:239-52.

16. Lippi G, Buonocore R, Schirosa F, Cervellin G: *Cardiac troponin I is increased in patients admitted to the emergency department with severe allergic reactions. A case-control study.* Int J Cardiol, 2015; 194: 68-69.

17. Gangadharan V, Bhatheja S, Al Balbissi K: *Kounis syndrome-An atopic monster for the heart.* Cardiovasc Diagn Ther, 2013; 3: 47-51.

18. Soufras GD, Kounis GN, Kounis NG: *Brain injury due to anaphylactic shock: broadening manifestations of Kounis syndrome.* Int Endod J, 2014; 47:309-13.

19. Peláez-Pérez JM, Sánchez Casado M, Álvarez-Twose I, Kounis NG: *Amoxicillin-clavulanic acid-induced type II Kounis syndrome during general anaesthesia complicated with hypoxic-ischaemic encephalopathy* [published online ahead of print, 2019 Aug 7]. Rev Esp Anesthesiol Reanim, 2019; S0034-9356(19)30123-9.

20. Gonzalez-de-Olano D, Alvarez-Twose I, Matito A, et al.: *Mast cell activation disorders presenting with cerebral vasospasm-related symptoms: a "Kounis-like" syndrome?* Int J Cardiol, 2011; 150: 210-11.

Nicholas G. Kounis*^o, Ioanna Koniari**^{*},
Grigorios Tsigkas*, Periklis Davlouros*

*Department of Cardiology, University of "Patras"
Medical School, Patras, Greece

**Electrophysiology and Device Department, University Hospital
of South Manchester NHS Foundation Trust, Manchester, UK

^o(e-mail: ngkounis@otenet.gr)